deltatrials
Completed OBSERVATIONAL NCT05213611

REported Outcomes in COPD With Trixeo in Real worlD (RECORD)

A Non-interventional, Multi-centre Study to Investigate the Change in Clinical and Patient-reported Outcomes in Moderate to Severe COPD Patients Treated With TRIXEO (Budesonide / Glycopyrronium / Formoterol) Under Real-life Conditions

Sponsor: AstraZeneca

Conditions Chronic Obstructive Pulmonary Disease
Updated 19 times since 2022 Last updated: Jul 8, 2025 Started: Aug 11, 2022 Primary completion: Jul 8, 2024 Completion: Jul 8, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Chronic Obstructive Pulmonary Disease, this trial is completed. The trial is conducted by AstraZeneca and has accumulated 19 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Feb 2022 – ~May 2022 · 3 months · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Jan 2023 · 2 months · monthly snapshot~Jan 2023 – ~Feb 2023 · 31 days · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~Apr 2023 · 31 days · monthly snapshot~Apr 2023 – ~Jun 2023 · 2 months · monthly snapshot~Jun 2023 – ~Jul 2023 · 30 days · monthly snapshot~Jul 2023 – ~Sep 2023 · 2 months · monthly snapshot~Sep 2023 – ~Dec 2023 · 3 months · monthly snapshot~Dec 2023 – ~Apr 2024 · 4 months · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Aug 2025 · 11 months · monthly snapshot~Aug 2025 – ~Sep 2025 · 31 days · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

19 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed

  2. Aug 2025 — Sep 2025 [monthly]

    Completed

  3. Sep 2024 — Aug 2025 [monthly]

    Completed

    Status: Active Not Recruiting → Completed

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting

  5. Apr 2024 — Jul 2024 [monthly]

    Active Not Recruiting

▶ Show 14 earlier versions

  1. Dec 2023 — Apr 2024 [monthly]

    Active Not Recruiting

  2. Sep 2023 — Dec 2023 [monthly]

    Active Not Recruiting

    Status: Recruiting → Active Not Recruiting

  3. Jul 2023 — Sep 2023 [monthly]

    Recruiting

  4. Jun 2023 — Jul 2023 [monthly]

    Recruiting

  5. Apr 2023 — Jun 2023 [monthly]

    Recruiting

  6. Mar 2023 — Apr 2023 [monthly]

    Recruiting

  7. Feb 2023 — Mar 2023 [monthly]

    Recruiting

  8. Jan 2023 — Feb 2023 [monthly]

    Recruiting

  9. Nov 2022 — Jan 2023 [monthly]

    Recruiting

  10. Sep 2022 — Nov 2022 [monthly]

    Recruiting

    Status: Not Yet Recruiting → Recruiting

  11. Jul 2022 — Sep 2022 [monthly]

    Not Yet Recruiting

  12. Jun 2022 — Jul 2022 [monthly]

    Not Yet Recruiting

  13. May 2022 — Jun 2022 [monthly]

    Not Yet Recruiting

  14. Feb 2022 — May 2022 [monthly]

    Not Yet Recruiting

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AstraZeneca
Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ashton-under-Lyne, United Kingdom , Bath, United Kingdom , Belfast, United Kingdom , Birkenhead, United Kingdom , Bury St Edmunds, United Kingdom , Carmarthen, United Kingdom , Cippenham, United Kingdom , Dewsbury, United Kingdom , Gillingham, United Kingdom , Gloucestershire, United Kingdom and 21 more locations